Mandate

VINGE ADVISES INDUSTRIFONDEN IN CONNECTION WITH THE FINANCING OF HASSELBLAD’S NEW CAMERAS

December 11, 2013

Industrifonden has provided financing to the camera maker, Hasselblad, in the form of a loan of approximately SEK 78 million with detachable options. The funds will be used for the launch of Hasselblad’s new series of cameras and for renewal of the existing range of cameras.

The new cameras will be available on the market shortly and the first two models, i.e. Lunar and Stellar, were launched recently. Since they are intended for amateur photographers, they are in a lower price and performance segment compared to Hasselblad’s traditional range of products, which are directed toward professional photographers.

Hasselblad’s current owner, the German-Swiss private equity firm, Vorndran Mannheims Capital, has made significant contributions in the form of renewal and greater degree of frequency of change of models in the existing H-system, where H5D was launched at the beginning of 2013.

Hasselblad’s production and R&D divisions are now based in Gothenburg where the company has doubled its production capacity and has recruited new personnel. Hasselblad is thus once again primarily a Swedish company.

Vinge’s team consisted of partner Johan Larsson and associate Lisa Antman.   

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024